RxDoctor Payments Data

Dilpreet Kaur, MD

Neurological Surgery · Modesto, CANPI 1639330301

Payments from drug & device makers

$1,492in general payments, 2019–2025

Across 98 payments — averaging $15.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$520
  • AbbVie$472
  • Biohaven Pharmaceutical Holding Company Ltd.$156
  • Biogen$96
  • Supernus Pharmaceuticals, Inc.$43
  • Lilly USA, LLC$39
  • plus $166 from 7 others

What the payments were for

  • Speaking & faculty fees$221%
  • Food & beverage$1,47099%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,492 in reported general payments places this provider in the 35th percentile of 773 neurological surgery providers in California.

See all neurological surgery providers in California

Medicare billing

Part B allowed, 2024
$96,646
Medicare patients
329
Services billed
708

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant50$67,203
Nurtec OdtRimegepant Sulfate39$38,838
Aimovig AutoinjectorErenumab-Aooe37$27,958
EliquisApixaban12$12,340
Carbidopa16$11,328
Rivastigmine59$9,427
Levetiracetam186$7,960
Memantine Hcl218$7,272
Carbidopa-LevodopaCarbidopa/Levodopa236$6,781
Lacosamide69$6,662
Duloxetine Hcl244$6,383
Rasagiline Mesylate15$4,975
RivastigmineRivastigmine Tartrate50$3,999
Donepezil Hcl217$3,056
Pregabalin118$3,039

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$472$67,20350 claims
PfizerNurtec Odt, Eliquis$18$51,17851 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 773 neurological surgery providers in California.

Other neurological surgery in Modesto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →